Literature DB >> 21681990

Discovery of biomarker candidates for coronary artery disease from an APOE-knock out mouse model using iTRAQ-based multiplex quantitative proteomics.

Linhong Jing1, Carol E Parker, David Seo, Maria Warren Hines, Nedyalka Dicheva, Yanbao Yu, Debra Schwinn, Geoffrey S Ginsburg, Xian Chen.   

Abstract

Due to the lack of precise markers indicative of its occurrence and progression, coronary artery disease (CAD), the most common type of heart diseases, is currently associated with high mortality in the United States. To systemically identify novel protein biomarkers associated with CAD progression for early diagnosis and possible therapeutic intervention, we employed an iTRAQ-based quantitative proteomic approach to analyze the proteome changes in the plasma collected from a pair of wild-type versus apolipoprotein E knockout (APOE(-/-) ) mice which were fed with a high fat diet. In a multiplex manner, iTRAQ serves as the quantitative 'in-spectra' marker for 'cross-sample' comparisons to determine the differentially expressed/secreted proteins caused by APOE knock-out. To obtain the most comprehensive proteomic data sets from this CAD-associated mouse model, we applied both MALDI and ESI-based mass spectrometric (MS) platforms coupled with two different schemes of multidimensional liquid chromatography (2-D LC) separation. We then comparatively analyzed a series of the plasma samples collected at 6 and 12 wk of age after the mice were fed with fat diets, where the 6- or 12-wk time point represents the early or intermediate phase of the fat-induced CAD, respectively. We then categorized those proteins showing abundance changes in accordance with APOE depletion. Several proteins such as the γ and β chains of fibrinogen, apolipoprotein B, apolipoprotein C-I, and thrombospondin-4 were among the previously known CAD markers identified by other methods. Our results suggested that these unbiased proteomic methods are both feasible and a practical means of discovering potential biomarkers associated with CAD progression.
Copyright © 2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21681990      PMCID: PMC4360897          DOI: 10.1002/pmic.201000202

Source DB:  PubMed          Journal:  Proteomics        ISSN: 1615-9853            Impact factor:   3.984


  31 in total

Review 1.  Proteomics for cancer biomarker discovery.

Authors:  Pothur R Srinivas; Mukesh Verma; Yinming Zhao; Sudhir Srivastava
Journal:  Clin Chem       Date:  2002-08       Impact factor: 8.327

2.  Advanced atherosclerotic lesions in the innominate artery of the ApoE knockout mouse.

Authors:  M E Rosenfeld; P Polinsky; R Virmani; K Kauser; G Rubanyi; S M Schwartz
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-12       Impact factor: 8.311

3.  Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature.

Authors:  E Ernst; K L Resch
Journal:  Ann Intern Med       Date:  1993-06-15       Impact factor: 25.391

4.  ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree.

Authors:  Y Nakashima; A S Plump; E W Raines; J L Breslow; R Ross
Journal:  Arterioscler Thromb       Date:  1994-01

5.  Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells.

Authors:  A S Plump; J D Smith; T Hayek; K Aalto-Setälä; A Walsh; J G Verstuyft; E M Rubin; J L Breslow
Journal:  Cell       Date:  1992-10-16       Impact factor: 41.582

6.  Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI.

Authors:  E M Rubin; R M Krauss; E A Spangler; J G Verstuyft; S M Clift
Journal:  Nature       Date:  1991-09-19       Impact factor: 49.962

7.  Large scale association analysis for identification of genes underlying premature coronary heart disease: cumulative perspective from analysis of 111 candidate genes.

Authors:  J J McCarthy; A Parker; R Salem; D J Moliterno; Q Wang; E F Plow; S Rao; G Shen; W J Rogers; L K Newby; R Cannata; K Glatt; E J Topol
Journal:  J Med Genet       Date:  2004-05       Impact factor: 6.318

8.  Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E.

Authors:  S H Zhang; R L Reddick; J A Piedrahita; N Maeda
Journal:  Science       Date:  1992-10-16       Impact factor: 47.728

9.  Familial hypoalphalipoproteinemia in premature coronary artery disease.

Authors:  J Genest; J M Bard; J C Fruchart; J M Ordovas; E J Schaefer
Journal:  Arterioscler Thromb       Date:  1993-12

10.  STRING 8--a global view on proteins and their functional interactions in 630 organisms.

Authors:  Lars J Jensen; Michael Kuhn; Manuel Stark; Samuel Chaffron; Chris Creevey; Jean Muller; Tobias Doerks; Philippe Julien; Alexander Roth; Milan Simonovic; Peer Bork; Christian von Mering
Journal:  Nucleic Acids Res       Date:  2008-10-21       Impact factor: 16.971

View more
  11 in total

Review 1.  Quantitative proteomics in cardiovascular research: global and targeted strategies.

Authors:  Xiaomeng Shen; Rebeccah Young; John M Canty; Jun Qu
Journal:  Proteomics Clin Appl       Date:  2014-07-14       Impact factor: 3.494

2.  Alterations in the cerebellar (Phospho)proteome of a cyclic guanosine monophosphate (cGMP)-dependent protein kinase knockout mouse.

Authors:  Eleonora Corradini; Raghavan Vallur; Linsey M Raaijmakers; Susanne Feil; Robert Feil; Albert J R Heck; Arjen Scholten
Journal:  Mol Cell Proteomics       Date:  2014-06-12       Impact factor: 5.911

3.  Proteomic Architecture of Human Coronary and Aortic Atherosclerosis.

Authors:  David M Herrington; Chunhong Mao; Sarah J Parker; Zongming Fu; Guoqiang Yu; Lulu Chen; Vidya Venkatraman; Yi Fu; Yizhi Wang; Timothy D Howard; Goo Jun; Caroline F Zhao; Yongmei Liu; Georgia Saylor; Weston R Spivia; Grace B Athas; Dana Troxclair; James E Hixson; Richard S Vander Heide; Yue Wang; Jennifer E Van Eyk
Journal:  Circulation       Date:  2018-06-19       Impact factor: 29.690

Review 4.  Biomarker discovery in mass spectrometry-based urinary proteomics.

Authors:  Samuel Thomas; Ling Hao; William A Ricke; Lingjun Li
Journal:  Proteomics Clin Appl       Date:  2016-02-11       Impact factor: 3.494

5.  Optimization of plasma sample pretreatment for quantitative analysis using iTRAQ labeling and LC-MALDI-TOF/TOF.

Authors:  Magdalena Luczak; Lukasz Marczak; Maciej Stobiecki
Journal:  PLoS One       Date:  2014-07-02       Impact factor: 3.240

6.  Proteomic analysis of differentially expressed proteins in the serum of patients with acute renal allograft rejection using iTRAQ labelling technology.

Authors:  Yue Zhang; Minglin Ou; Hua Lin; Liusheng Lai; Huaizhou Chen; Jiejing Chen; Weiguo Sui; Wen Xue; Ruohan Zhang; Qing Gan; Donge Tang; Xuyong Sun; Jianhui Dong; Qiang Yan; Yong Dai
Journal:  Mol Med Rep       Date:  2020-07-06       Impact factor: 2.952

Review 7.  Characterization and Quantification of Selenoprotein P: Challenges to Mass Spectrometry.

Authors:  Jérémy Lamarche; Luisa Ronga; Joanna Szpunar; Ryszard Lobinski
Journal:  Int J Mol Sci       Date:  2021-06-11       Impact factor: 5.923

8.  Vascular Proteomics Reveal Novel Proteins Involved in SMC Phenotypic Change: OLR1 as a SMC Receptor Regulating Proliferation and Inflammatory Response.

Authors:  Dong Hoon Kang; Mina Choi; Soyoung Chang; Min Young Lee; Doo Jae Lee; Kyungsun Choi; Junseong Park; Eun Chun Han; Daehee Hwang; Kihwan Kwon; Hanjoong Jo; Chulhee Choi; Sang Won Kang
Journal:  PLoS One       Date:  2015-08-25       Impact factor: 3.240

Review 9.  Effects of hypertension and exercise on cardiac proteome remodelling.

Authors:  Bernardo A Petriz; Octavio L Franco
Journal:  Biomed Res Int       Date:  2014-04-27       Impact factor: 3.411

10.  Molecular phenotyping of laboratory mouse strains using 500 multiple reaction monitoring mass spectrometry plasma assays.

Authors:  Sarah A Michaud; Nicholas J Sinclair; Helena Pětrošová; Andrea L Palmer; Adam J Pistawka; Suping Zhang; Darryl B Hardie; Yassene Mohammed; Azad Eshghi; Vincent R Richard; Albert Sickmann; Christoph H Borchers
Journal:  Commun Biol       Date:  2018-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.